04 Apr 2023
A joint safety alert has been issued from the British Menopause Society, Faculty of Sexual & Reproductive Healthcare, Royal College of General Practitioners, Royal College of Obstetricians & Gynaecologists, Society for Endocrinology and the Royal College of Nursing Women’s Health Forum.
This safety alert has been produced in response to questions raised in relation to appropriate doses of oestrogen and progestogen provided to women experiencing symptoms of menopause.
Current National Institute for Health and Care Excellence (NICE), MHRA and national and international guidance recommends the lowest effective dose to control symptoms, but an increasing numbers of women are being initiated on high doses of oestrogen which exceed the product licenses, not in line with any clinical guidelines.
Read the alert in full.
Join the Clinical Committee as a Co-Opted Member
18 Sep 2023
Update from Ferring Pharmaceuticals regarding Desmopressin
18 Sep 2023
Link between premenopausal bilateral oophorectomy and chronic illness
15 Sep 2023
COVID-19 vaccination associated with risk of thyroid associated eye disease
15 Sep 2023
Breakthrough AI system may improve treatment of debilitating diseases
15 Sep 2023
